Enanta Pharmaceuticals Inc. (ENTA) Sees Large Volume Increase
Enanta Pharmaceuticals Inc. (NASDAQ:ENTA) shares saw strong trading volume on Tuesday . 347,367 shares traded hands during mid-day trading, an increase of 26% from the previous session’s volume of 275,011 shares.The stock last traded at $27.11 and had previously closed at $25.65.
A number of analysts recently weighed in on the stock. Zacks Investment Research upgraded shares of Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, August 12th. JPMorgan Chase & Co. set a $26.00 price target on shares of Enanta Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, August 9th. One analyst has rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $26.58.
The company has a market cap of $509.19 million, a PE ratio of 17.69 and a beta of 0.58. The company has a 50 day moving average of $22.93 and a 200 day moving average of $25.07.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/enanta-pharmaceuticals-inc-enta-sees-large-volume-increase.html
Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings results on Monday, August 8th. The company reported ($0.06) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.09) by $0.03. The company had revenue of $14 million for the quarter, compared to analysts’ expectations of $13.07 million. Enanta Pharmaceuticals had a return on equity of 11.31% and a net margin of 32.59%. The business’s quarterly revenue was up 20.7% compared to the same quarter last year. During the same period in the previous year, the business posted $0.13 earnings per share. Analysts anticipate that Enanta Pharmaceuticals Inc. will post $1.02 earnings per share for the current fiscal year.
Several hedge funds have recently added to or reduced their stakes in ENTA. Public Employees Retirement System of Ohio boosted its stake in Enanta Pharmaceuticals by 4.0% in the second quarter. Public Employees Retirement System of Ohio now owns 19,209 shares of the company’s stock valued at $424,000 after buying an additional 747 shares during the period. Fiera Capital Corp purchased a new stake in Enanta Pharmaceuticals during the second quarter valued at $12,480,000. AQR Capital Management LLC boosted its stake in Enanta Pharmaceuticals by 6.5% in the second quarter. AQR Capital Management LLC now owns 46,258 shares of the company’s stock valued at $1,020,000 after buying an additional 2,822 shares during the period. Guggenheim Capital LLC boosted its stake in Enanta Pharmaceuticals by 16.2% in the second quarter. Guggenheim Capital LLC now owns 36,718 shares of the company’s stock valued at $809,000 after buying an additional 5,118 shares during the period. Finally, Senzar Asset Management LLC boosted its stake in Enanta Pharmaceuticals by 42.2% in the second quarter. Senzar Asset Management LLC now owns 482,000 shares of the company’s stock valued at $10,628,000 after buying an additional 143,149 shares during the period. Institutional investors own 70.82% of the company’s stock.
Enanta Pharmaceuticals Company Profile
Enanta Pharmaceuticals Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create molecule drugs primarily for the treatment of viral infections and liver diseases. The Company is engaged in discovering and developing inhibitors designed for use against the hepatitis C virus (HCV), as well as compounds for non-alcoholic steatohepatitis (NASH) and primary biliary cirrhosis (PBC).
Receive News & Ratings for Enanta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.